(2E,4E,6E,8E)-N-(3-trifluoromethylphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide | 1197356-44-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (2E,4E,6E,8E)-N-(3-trifluoromethylphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide
• 英文别名: (3-trifluoromethylphenyl)-(all-trans)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate；(3-trifluoromethylphenyl)-(all-trans)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid amide；(2E,4E,6E,8E)-3,7-dimethyl-N-[3-(trifluoromethyl)phenyl]-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
• CAS: 1197356-44-7
• 化学式: C₂₇H₃₂F₃NO
• 分子量: 443.552
• InChiKey: XGSMEEHHAVIWPH-SWPINJBASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  维A酸 、 间氨基三氟甲苯 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 以67%的产率得到(2E,4E,6E,8E)-N-(3-trifluoromethylphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide
  参考文献：
  名称：

  芬维A胺类似物作为抗癌和代谢综合症的预防剂的设计，合成，放射合成和生物学评估。

  摘要：

  Fenretinide（4-HPR）是全反式视黄酸（ATRA）的合成衍生物，具有相对于ATRA更高的治疗特性和毒理学特征。4-HPR作为抗癌药已被广泛研究，但最近的研究表明，4-HPR在预防代谢综合征方面具有广阔的前景。4-HPR的活性涉及多个生物学靶标，导致该分子可能用于治疗不同的病理学。然而，尽管4-HPR在药理学方面显示出了很好理解的多靶点混杂性，但解释其确切的生理作用仍然具有挑战性。此外，尽管体外试验结果令人满意，到目前为止，4-HPR作为化学治疗剂的临床疗效尚不令人满意。本文中，我们描述了4-HPR类似物文库的制备，然后对其抗癌和抗肥胖/糖尿病特性进行了生物学评估。点击型类似物3b在分化过程中显示出良好的能力来减少3T3-L1脂肪细胞中脂质的积累。此外，在乳腺癌细胞系MCF-7的细胞活力测试中，IC 50为0.53±0.8μM，并且对非癌性HEK293细胞具有良好的选择性（SI =

  DOI：

  10.1002/cmdc.202000143

文献信息

• Retinoid Derivative and Pharmaceutical Composition and Use Thereof
  申请人：Chen Feihu

  公开号：US20110077298A1

  公开（公告）日：2011-03-31

  The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumours, such as acute leukemia, chronic leukemia, multiple myeloma and lymphoma, solid tumours, such as liver cancer, rectal cancer, mammary cancer and esophagus cancer, and skin disorders, such as psoriasis and acne.

  这项发明涉及一种视黄醇衍生物及其药物组合物和用途。该发明的化合物能够预防或治疗血液肿瘤，如急性白血病、慢性白血病、多发性骨髓瘤和淋巴瘤，实体肿瘤，如肝癌、直肠癌、乳腺癌和食道癌，以及皮肤疾病，如银屑病和痤疮。
• RETINOID DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
  申请人：Anhui Medical University

  公开号：EP2279999B1

  公开（公告）日：2015-05-27
• USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN
  申请人：Fabius Biotechnology

  公开号：US20210338558A1

  公开（公告）日：2021-11-04

  The present invention addresses the need for an improved delivery system that is able to specifically target the skin for improved bioavailability and minimization of side effects resulting from administration of the active ingredient or ingredients. One aspect of the present invention is a targeting composition comprising: (1) a skin care agent or an agent that is a cosmeceutical agent; (2) an intermediate release linker bound to the skin care agent or cosmeceutical agent; (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers; and (4) optionally, a carrier component to enhance delivery to the skin. The present invention also describes methods of use of these targeting compositions.
• US8110703B2
  申请人：——

  公开号：US8110703B2

  公开（公告）日：2012-02-07
• [EN] USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN<br/>[FR] UTILISATION DE DOMAINES DE LIAISON AU COLLAGÈNE POUR DÉLIVRER DES PRODUITS À LA PEAU
  申请人：FABIUS BIOTECHNOLOGY

  公开号：WO2020068665A1

  公开（公告）日：2020-04-02

  The present invention addresses the need for an improved delivery system that is able to specifically target the skin for improved bioavailability and minimization of side effects resulting from administration of the active ingredient or ingredients. One aspect of the present invention is a targeting composition comprising: (1 ) a skin care agent or an agent that is a cosmeceutical agent; (2) an intermediate release linker bound to the skin care agent or cosmeceutical agent; (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers; and (4) optionally, a carrier component to enhance delivery to the skin. The present invention also describes methods of use of these targeting compositions.